Another great win for aspirin, especially considering the prevalence of NAFLD, NASH, fibrosis/cirrhosis and even liver cancer. This post comes mere minutes after the post on a single tablet aspirin (300mg) daily putting a terminal liver cancer in remission. This study below used a low-dose (81mg) aspirin, but given the benefits of the “high-dose” (300mg) in the prior study I don’t see a reason not to try higher doses for even stronger effects in NAFLD/NASH/fibrosis cases.
https://www.natap.org/2023/AASLD/AASLD_100.htm
https://www.medscape.com/viewarticle/998550
“…Patients with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) without cirrhosis who took daily low-dose aspirin in a double-blind randomized trial demonstated significant reductions in liver fat content over 6 months compared with similar patients who took a placebo, study results show. “In MASLD without cirrhosis, low-dose aspirin, 81 milligrams daily, led to decreases in liver fat and improved markers of hepatic inflammation and fibrosis,” reported Robert M. Wilechansky, MD, a transplant hepatology fellow at Massachusetts General Hospital in Boston. “It was safe and well tolerated in this study, but we would like to see larger, longer-term clinical trials to test the efficacy of aspirin for improving histology and preventing adverse outcomes in MASLD,” he said here at The Liver Meeting 2023: American Association for the Study of Liver Diseases (AASLD).”
“…Aspirin was also associated with significantly greater reductions in liver transaminase levels and liver stiffness by VCTE. About one third of patients in each study arm had at least one adverse event. There was only one aspirin-related adverse event (heartburn) that led to discontinuation. There were no serious bleeding events in either arm. “We’re going to have to consider stratifying by aspirin use now in our trials,” said Mark Hartman, MD, from Eli Lilly & Co. in Indianapolis.”
